Fig. 1From: Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthmaStaggered trial design of STRATOS 1 and 2. Q2W, every 2 weeks; Q4W, every 4 weeks; SC, subcutaneousBack to article page